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ABSTRACT
Invasive adenovirus (AdV) disease is fatal in >50% of allogeneic hematopoietic stem cell transplant (SCT) recipi-
ents. Treatment with cidofovir may improve outcomes based on in vitro susceptibility data and case reports. Six
consecutive cases of invasive AdV disease treated with cidofovir were reviewed among 84 allogeneic adult SCT
recipients (incidence, 7.1%). Cidofovir was administered intravenously at 5 mg/kg per dose (1-7 doses). All patients
received intravenous immune globulin. Blood AdV DNA levels (viral loads, VLs) were monitored with a real-time
quantitative polymerase chain reaction assay. Published reports of cidofovir treatment of AdV disease in SCT
recipients were critically reviewed. The primary manifestations of AdV disease were hepatitis (n  3), colitis (n 
2), and nephritis (n 1). All patients had detectable AdV VLs, with peak values from 5 105 to 2 108 copies/mL.
All patients received CD34 selected grafts (n  3) and/or had graft-versus-host disease (n  4) and had CD4
counts<100 cells/mm3. Only 1 of 5 patients (20%) who received>2 doses of cidofovir died with active AdV disease.
Four patients exhibited improvement within days of treatment with cidofovir as documented by clinical criteria and
declines in AdVVLs (without a change in immunosuppression). In contrast, 1 patient treated late after onset of AdV
disease died after 1 dose of cidofovir. In our review of 70 published cases treated with >2 doses of cidofovir, 13
(19%) died from AdV disease. In conclusion, early treatment of AdV disease with cidofovir inhibits viral replication
in vivo and reduces mortality in allogeneic SCT recipients compared with historical data.
© 2007 American Society for Blood and Marrow Transplantation
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dNTRODUCTION
Opportunistic pathogens such as adenovirus (AdV)
ave emerged in the hematopoietic stem cell transplant
SCT) recipient population as new techniques have re-
uced the risk of graft-versus-host disease (GVHD) but
esulted in more profound and prolonged immunosup-
ression. SCT recipients are susceptible to invasive in-
ections caused by AdV, including pneumonitis, hepati-
is, colitis, and hemorrhagic cystitis [1-4]. AdV infections
ccur more frequently in pediatric than in adult
CT recipients [2,5,6]. Patients who receive an al-
ogeneic transplant, in particular with a T cell-
epleted or CD34 (stem cell) selected graft, and
atients who develop GVHD have a higher inci-
ence of AdV infection [7]. p
4Until recently, ribavirin was the only antiviral
gent used against AdV infections, and responses
ere limited [5,8,9]. Cidofovir is a monophosphate
ucleotide analogue of cytosine that inhibits viral
NA polymerases and exhibits activity against mul-
iple DNA viruses. Cidofovir has been shown to
ave in vitro activity against AdV [10]. Since 1999,
here have been a number of case reports of cido-
ovir use in SCT recipients with AdV infection
3,9,11-14].
Based on the in vitro data and case reports with
idofovir, we started to treat our adult allogeneic SCT
ecipients who developed invasive AdV disease with ci-
ofovir in 2003. In this report, we describe 6 consecutive
atients who developed invasive AdV infections and
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Cidofovir Treatment of Adenovirus Disease in SCT 75ere treated with cidofovir. A real-time quantitative
olymerase chain reaction (PCR) in plasma (viral load,
L) was used to measure AdV replication and to mon-
tor the response to cidofovir treatment. In addition, a
ritical review of the literature on the use of cidofovir for
dV disease in SCT recipients was performed.
ETHODS
atients
Six consecutive cases of AdV disease diagnosed in
dult SCT recipients at Thomas Jefferson University
ospital from 2003 to 2005 were reviewed retrospec-
ively. This study was approved by the institutional
eview board.
ransplant Conditioning Regimens
Three patients (cases 1, 3, and 4) received CD34
elected transplants after a myeloablative preparatory
egimen consisting of ﬂudarabine, cytarabine, mel-
halan, and antithymocyte globulin. CD34 selection
as performed using the Isolex 300i Magnetic cell
elector (Nexell Therapeutics, Irvine, Calif). Two pa-
ients (cases 2 and 5) received non-myeloablative
rafts using a preparative regimen of ﬂudarabine, cyt-
rabine, and cyclophosphamide. The sixth patient re-
eived a myeloablative regimen consisting of total
ody irradiation and cyclophosphamide with an un-
anipulated peripheral stem cell product.
onor Lymphocyte Infusions
All patients who received T cell-depleted grafts
ere treated with donor lymphocyte infusion (DLI) to
xpedite immune reconstitution, as part of an investi-
ational study (manuscript in preparation). To reduce
he risk of GVHD, donor lymphocytes were modiﬁed
y treatment with L-leucyl-L-leucine methyl ester to
eplete perforin-containing cells (primarily CD8 T
ells and natural killer cells) [15,16].
iral Cultures
Urine, stool, throat, respiratory, and tissue speci-
ens were cultured with the R-mix shell vial system
Diagnostic Hybrids, Athens, Ohio).
uantitative AdV PCR
Blood specimens were assayed with a quantitative
eal time AdV DNA PCR assay (ViraCor, Lee’s Sum-
it, Mo). Urine, cerebrospinal ﬂuid (CSF), and tissue
pecimens were tested as clinically indicated.
efinition of AdV Disease
AdV disease was deﬁned as a positive AdV culture
rom a tissue biopsy with compatible clinical signs and
ymptoms and no other identiﬁable causes. In 1 case of Temorrhagic cystitis and probable nephritis (patient 6),
dV disease was diagnosed by a positive urine AdV
ulture, a positive AdV VL, in addition to fever, hema-
uria, bilateral ﬂank pain, and elevated creatinine. All
atients had extensive workups to exclude other patho-
ens, including routine, fungal, acid fast bacilli, and viral
ultures, and PCR tests for cytomegalovirus, Epstein-
arr virus, and BK virus, as clinically indicated.
reatment
All patients diagnosed with AdV disease were treated
ith intravenous cidofovir and intravenous immuno-
lobulin (IVIG). Cidofovir was dosed at 5 mg/kg intra-
enously every week for the ﬁrst 2 weeks, followed by
very other week, for a minimum of 4 doses in patients
ho survived (range, 1-7 doses). Patients were prehy-
rated before each dose, and probenecid was adminis-
ered according to themanufacturer’s recommendations.
VIG dosing varied, but patients were generally given
-2 g/kg, followed by 500 mg/kg administered every
ther week for a minimum of 4 doses.
ASE REPORTS (TABLES 1 AND 2)
atient 1
A 23-year-old man with chronic myelogenous leu-
emia in T lymphoblastic crisis received a T cell-de-
leted, matched related SCT. He was admitted 88 days
fter transplantation with chills and fevers. A liver biopsy
erformed for elevated transaminases was nondiagnostic.
e received IVIG and a scheduled DLI and was dis-
harged. He was readmitted on day 112 with recurrent
evers, new right upper quadrant pain, and worsening
ransaminases. The liver biopsy viral culture was now
ositive for AdV, and the AdV VL was 1.6 106 copies/
L. Treatment with cidofovir was initiated, and IVIG
as redosed. The patient developed prompt resolution
f the fevers (within 48 hours) and rapid improvement of
is transaminases and AdV VL (Figure 1, case 1). The
atient remained asymptomatic at 6-month follow-up
ith negative AdV VLs.
atient 2
A 42-year-old woman with multiple myeloma re-
eived an autologous SCT followed by a non-myeloab-
ative matched related SCT. On day 23 after allogeneic
ransplantation, she was admitted with nausea, vomiting,
nd diarrhea. Colonoscopy revealed GVHD of the large
owel, which was treated with initial improvement. On
ay 53, her diarrhea and abdominal pain worsened and
er transaminases became mildly elevated. Upper and
ower endoscopic biopsies were nondiagnostic, but the
iral culture and PCR from the duodenum biopsy were
ositive for AdV. IVIG and treatment with cidofovir
ere initiated without a change in immunosuppression.
he patient showed prompt clinical improvement and
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D. Neofytos et al.76ormalization of her transaminases and AdV VL (Figure
, case 2). The AdV VLs remained negative despite
ngoing GVHD and immunosuppressive therapy at
-month follow-up.
atient 3
A 39-year-old man with relapsed acute lymphoblas-
ic leukemia received a T cell-depleted, haploidentical
able 1. Patient Characteristics and AdV Disease Manifestations
1 2
ge 23 4
iagnosis CML MM
ype of transplant MRD MR
cell depletion  
mmunosuppression
Steroids  
Cyclosporine  
MMF  
Tacrolimus  
Sirolimus  
Infliximab  
ATG  
VHD  GI
dV disease Hepatitis Col
irst positive AdV test (days after SCT) 91 5
utcome (6 mo) Alive Aliv
ML indicates chronic myelogenic leukemia; MM, multiple myelo
MRD, matched related donor; Haplo, haploidentical donor; M
anti-thymocyte globulin; GVHD, graft-versus-host disease; GI,
Non-myeloablative.
able 2. Laboratory Tests, Signs, and Symptoms of Adenovirus Disease
1 2
dV culture
Feces  (90)  (57)
Urine  (99)  (58)
Throat  (91) ND
BAL ND ND
Tissue Liver (98) Duodenum (59)
dV VL (copies/mL)
Setpoint 2.06  105 (92) 1500 (59)
Peak 1.6  106 (110) 5.3  104 (62)
idofovir start day 113 66
VIG start day 95 56
LI days 102 ND
igns/symptoms
Fever  
Diarrhea  
Abdominal pain  
Cough/dyspnea  
Dysuria  
MS changes  
Abnormal LFTs  
ymphocyte counts
(cells/mm3)
CD4/CD8 5/5 (92) NDD indicates not done; BAL, bronchoalveolar lavage; DLI, donor lymphCT. On day 30 he received a boost of stem cells for
one marrow failure. He developed a biopsy-conﬁrmed
diopathic pneumonitis (day 48) and was treated with
nﬂiximab, with improvement. On day 51 the patient
eceived a DLI. He developed diarrhea, and a sigmoid
iopsy (day 68) was nondiagnostic, but the viral culture
as positive for AdV and an AdV VL was 7400 copies/
L. The patient was treated with IVIG, and his diarrhea
Cases
3 4 5 6
39 43 72 33
ALL AML AML AML
Haplo MRD MUD* MRD
   
   
   
   
   
   
   
   
 Skin Skin and GI Liver
Hepatitis Hepatitis Colitis Nephritis
Colitis Pneumonia Hepatitis Cystitis
68 187 64 214
Died (4 d) Alive Died (2 wk) Alive
L, acute lymphocytic leukemia; AML, acute myelogenic leukemia;
matched unrelated donor; MMF, mycophenolate mofetil; ATG,
intestinal tract; SCT, stem cell transplantation.
eatment
es (Days after SCT)
3 4 5 6
(75)  (195) ND ND
(81)  (197) ND  (214)
ND  (67) ND
(48)  (195) ND ND
oid (78) Liver (197) Sigmoid (69) ND
0 (68) 6.9  104 (187) 1.9  105 (64) 8.6  104 (214)
08 (96) 6.7  107 (197) 7.4  107 (70) 7.9  105 (222)
93 197 68 218
77 197 68 218
51 47 125 ND ND
   
   
   
   
   
   
   
(75) 12/34 (200) 21/2 (77) 63/132 (214)2
D*
itis
9
e
ma; AL
UD,
gastroand Tr
Cas


ND

Sigm
740
2  1
10/4ocyte infusion; MS, mental status; LFTs, liver function tests.
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Cidofovir Treatment of Adenovirus Disease in SCT 77ecreased. On day 84 he developed mildly elevated
ransaminases and underwent an open cholecystectomy,
ithout improvement. On day 91 he became febrile, his
ransaminases rapidly worsened, and his AdV VL in-
reased to 2  108 copies/mL (Figure 1, case 3). IVIG
nd cidofovir were initiated, but the patient expired 4
ays later from fulminant hepatitis.
atient 4
A 43-year-old man with acute myelogenous leuke-
ia (AML) received a T cell-depleted, matched related
CT. He received DLI after transplantation and devel-
ped skin GVHD (day 160) that responded to treat-
ent. He was admitted on day 190 with Pseudomonas
eruginosa septicemia and mildly elevated transaminases.
is immunosuppressive regimen was tapered, but his
igure 1. Plots of the adenovirus viral loads (AdV VL) and aspartate
onor lymphocyte infusion; IVIG, intravenous immunoglobulin.evers persisted and liver function tests worsened. A mhest computed tomogram displayed patchy areas of
irspace disease involving both lungs. Transbronchial
ung biopsy was nondiagnostic. Liver biopsy revealed
ecrotic foci consistent with viral hepatitis, but no viral
nclusions were visualized. The bronchoalveolar lavage
nd liver viral cultures were positive for AdV. He devel-
ped mental status changes and had a negative head
omputed tomogram; his CSF had no cells but was AdV
CR positive. Upon treatment with IVIG and cidofovir,
is fevers, mental status, transaminases, and AdV VLs
romptly improved (Figure 1, case 4). At 6-month fol-
ow-up, he had recurrent leukemia without a relapse of
dV disease.
atient 5
A 72-year-old man with AML received a non-
transferase (AST) levels in cases 1-6. CDV indicates cidofovir; DLI,aminoyeloablative matched unrelated SCT. On day 31, he
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D. Neofytos et al.78as started on high-dose steroids for skin GVHD. A
olonoscopy performed on day 35 also revealed
VHD, and his immunosuppression was intensiﬁed.
ixty days after transplantation, the patient developed
ilateral conjunctivitis, transaminase elevations, and
orsening diarrhea. Repeat sigmoid colon biopsy re-
ealed GVHD and was also culture-positive for AdV,
nd his AdV VL was 188 000 copies/mL. The AdV
L and transaminases started to decrease after treat-
ent with cidofovir, and IVIG was initiated (Figure 1,
ase 5). However, the patient’s diarrhea subsequently
orsened, and he became lethargic. Brain magnetic
esonance imaging on day 82 showed abnormalities
onsistent with rhombencephalitis, and he expired the
ollowing day.
atient 6
A 33-year-old man with AML received an unma-
ipulated matched related SCT. On day 169, he de-
eloped hepatic GVHD, which was treated with a
ood response. On day 205, he developed acute onset
f dysuria, hematuria, and bilateral ﬂank pain. A urine
CR test for BK virus was positive once (600 copies/
L) and was negative thereafter. Ultrasound of the
idneys revealed mild bilateral hydronephrosis. The
atient was treated with intravenous hydration, and
is immunosuppression was tapered without improve-
ent. A bladder biopsy revealed a denuded bladder
all with mild chronic submucosal inﬂammation. On
ay 212 he started to have daily fevers to 103°F, and
is creatinine level increased to 1.9 mg/dL. Treatment
ith cidofovir and IVIG was initiated after a positive
rine culture for AdV and elevated AdV VLs were
oted. His fevers and ﬂank pain promptly resolved
within 48-72 hours), followed by improvement in his
reatinine, dysuria, hematuria, and AdV VLs (Figure
, case 6). The patient remained asymptomatic at 6
onths with negative AdV VLs.
ESULTS
Six cases of AdV disease were identiﬁed among 84
llogeneic adult SCT recipients performed during
003 to 2005, representing an incidence of 7.1%.
atient characteristics are summarized in Table 1. All
atients received T cell-depleted grafts (n  3) and/or
eveloped GVHD (n  4). Patients’ median age was
0.5 years (range, 23-72 years).
denovirus Disease
All 6 patients developed fever, and the liver was
he most common site of invasive AdV disease (Tables
and 2). Hepatitis was the primary diagnosis in 3
atients (cases 1, 3, and 4), and 2 additional patients
ad abnormal liver function test results (cases 2 and 5).
olitis was the primary diagnosis in 2 patients (cases 2 mnd 5) and the initial presentation in case 3. One
atient (case 6) developed AdV hemorrhagic cystitis
nd probable nephritis. Two patients had evidence of
neumonitis (cases 1 and 4). In addition, 2 patients
ad mental status changes with possible encephalitis:
ase 4 had a positive CSF AdV PCR result (without
ells in CSF) and case 5 had rhombencephalitis on
rain magnetic resonance imaging (lumbar puncture
as not performed). The median onset of AdV infec-
ion (ﬁrst positive test result) was 114 days after trans-
lantation (range, 59-214 days).
dV Culture Results
Tissue biopsies were performed in all patients
Table 2). Liver biopsies were performed in cases 1
nd 4, and viral cultures were positive for AdV. Pa-
ients 2, 3, and 5 underwent endoscopic biopsies: viral
ultures were positive for AdV in specimens obtained
rom the duodenum in patient 2 and the sigmoid
olon in patients 3 and 5. Liver biopsy was not per-
ormed in case 3 (with prior AdV colitis), but his
arkedly abnormal liver function test results and high
dV VLs were highly suggestive of fulminant AdV
epatitis. Patient 6 had a positive urine culture for
dV and underwent cystoscopic biopsy, but tissue was
ot sent for viral culture. AdV isolates from all cases
except case 3) were sent for serotyping: AdV type 1
as identiﬁed from cases 1 and 2 (Quest Diagnostics,
eterboro, NJ), 4 (State Lab, Lionville, Pa), and 5
Focus Technologies, Cypress, Calif); the isolate from
ase 6 was not typable. Notably, none of the biopsy
pecimens had viral inclusions identiﬁed on routine
istopathology.
dV Viral Loads
All 6 patients had positive AdV VLs that were
ollowed prospectively, as illustrated in Figure 1.
lood was tested retrospectively in cases 1, 3 and 4 and
ound to be positive for AdV in all 3 cases, preceding
he onset of clinical symptoms by a mean of 20 days.
he AdV VL peaked within a median of 9 days after
nset of clinical symptoms and remained positive for a
edian of 29.5 days. There was a wide range in VLs
mong the 6 cases, with the peak value ranging from
3 400 copies/mL to 2  108 copies/mL.
ymphocyte Counts
Lymphocyte counts with subset ﬂow cytometric
nalysis were followed in cases 1, 3, 4, 5, and 6 (Table
). Three of these patients received T cell-depleted
rafts (cases 1, 3, and 4), followed by modiﬁed DLI.
or patient 1, the absolute CD4 and CD8 T cell
ounts were 10 cells/mm3 at the time of onset of
dV disease (day 92). He received DLI on day 102,
nd his CD4 count increased to 333 and 460 cells/
m3 on days 124 and 153, respectively. Patient 3 had
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Cidofovir Treatment of Adenovirus Disease in SCT 79rofoundly low T cell counts (10 cells/mm3 each)
hroughout his hospital course despite treatment with
LI. Although patient 4 also received DLI, he had
ery low T cell counts (50 cells/mm3 each) because
e developed AdV disease while receiving treatment
or GVHD after DLI. The remaining 3 patients re-
eived intensive immunosuppressive therapy for
VHD (Table 1) and had CD4 counts (absolute lym-
hocyte count in case 2) 100 cells/mm3 at the time
f diagnosis of AdV disease.
utcomes
All 6 patients were treated with cidofovir. Four of
patients (80%) who received 2 doses of cidofovir
ad prompt responses as documented by clinical cri-
eria and declines in AdV VLs. One patient with
ulminant AdV hepatitis at the time treatment with
idofovir was initiated died 4 days later. Although
idofovir is highly nephrotoxic, none of the patients
equired treatment interruption. The baseline creati-
ine level was abnormal (up to 1.9 mg/dL) in case 6
nd improved upon treatment with cidofovir, consis-
ent with the diagnosis of AdV nephritis. However,
ost patients developed transient elevations in creat-
nine as the number of doses increased.
ISCUSSION
Invasive AdV disease in allogeneic SCT recipients
as been associated with fatal outcomes, with mortal-
ties averaging 50% (range, 27%-65%) [5,8,9,17]. Al-
hough there is no documented effective therapy, un-
ontrolled studies and case reports have described
linical responses to cidofovir. The present report
escribes 6 detailed cases of documented AdV disease
n adult SCT recipients who were treated with cido-
ovir and monitored with a quantitative AdV PCR
ssay. All patients were severely immunocompromised
ith CD34 selected grafts (n  3) and/or GVHD
n 4) and had CD4 counts100 cells/mm3. Four of
patients (80%) who received 2 doses of cidofovir
ad prompt responses, documented by clinical criteria
nd declines in AdV VLs, and recovered from AdV
isease. One patient who died from fulminant AdV
epatitis 4 days after a single dose of cidofovir was not
valuable.
AdV disease was documented in all cases by pos-
tive AdV viral cultures from tissue specimens (cases
-5) and a positive urine AdV culture and AdV VL in
ase 6. AdV type 1 was identiﬁed from 4 typed isolates
cases 1, 2, 4, and 5). In addition, all patients had
ompatible clinical presentations and were extensively
valuated to exclude other pathogens. Tissue biopsies
ailed to reveal viral inclusions in any case, although in
ase 4 the liver biopsy was interpreted as consistent
ith viral hepatitis. These cases illustrate the poor Tensitivity of routine histopathology in detecting AdV
isease in comparison with viral culture.
All 6 patients with AdV disease had detectable
iremia, with peak AdV VLs ranging from 5  104 to
 108 copies/mL. The 4 patients with VLs 106
opies/mL (cases 1, 3, 4, and 5), were most intensely
mmunosuppressed and developed the most severe
dV disease; 2 of 4 died related to AdV disease.
iremia has previously been associated with dissemi-
ated AdV disease [3,14,18]. In addition, Claas et al
19] found that VLs 106 copies/mL were associated
ith an increased risk for fatal disease. These data
upport the utility of monitoring AdV VLs in patients
ith AdV disease.
In 4 cases (1, 2, 4, and 6), dramatic clinical re-
ponses and reductions in AdV VLs were observed
ithin days after treatment with cidofovir (Figure 1).
n particular, T cell-depleted recipients 1 and 4 were
xtremely immunocompromised (T cell counts 20
ells/mm3) and developed severe hepatitis with AdV
Ls 106 copies/mL. Based on our past experience
ith this population, both patients would likely have
ad fatal outcomes without therapy. Notably, patient
also received a DLI around the time of onset of AdV
isease, and his CD4 and CD8 counts increased
ithin 4 weeks to 333 and 1000 cells/mm3, respec-
ively. Although his initial prompt improvement was
oincident with cidofovir treatment, his immune re-
overy likely contributed to the eventual resolution of
is AdV infection. Patient 4 developed AdV disease 4
eeks after starting high-dose steroids, cyclosporine,
nd mycophenolate mofetil for GVHD after DLI. His
apid improvement was likely due to the cidofovir,
ecause his immune recovery after DLI was delayed
y the GVHD and immunosuppressive therapy. Im-
unosuppression was not tapered in case 2 secondary
o active GVHD. In patient 6, his symptoms worsened
espite tapering his immunosuppression, but he had a
apid clinical response and decrease in AdV VLs co-
ncident with treatment with cidofovir. Therefore, the
rompt responses observed in these cases were likely
ue to cidofovir treatment rather than the administra-
ion of DLI or reduction in immunosuppression.
Two patients (cases 3 and 5) died with active AdV
isease. Patient 3 did not receive cidofovir until after
e developed fulminant hepatitis, and he died a few
ays later. It is tempting to speculate whether or not
arlier treatment when he initially developed colitis
ay have improved his outcome. Patient 5 had an
nitial response to cidofovir with reduction in AdV
Ls despite active GVHD and older age but then
uccumbed due to probable AdV encephalitis and on-
oing GHVD.
IVIG was also administered to all patients, but no
eﬁnite conclusions can be made about its effect.
hree patients were ﬁrst treated with IVIG alone
(
w
v
a
s
u
r
t
p
d
s
d
c
c
S
A
c
l
G
g
t
t
t
t
N
[
v
c
o
v
i
p
b
m
A
t
d
t
r
r
i
r
V
i
n
r
t
r
m
t
w
A
C
a
s
n
e
T
R
L
B
H
S
L
L
M
K
P
*
†
‡
§
D. Neofytos et al.80cases 1, 2, and 3), and IVIG may have been associated
ith a transient response in case 3 only (Figure 1).
Previous reports that described the use of cidofo-
ir in SCT recipients with AdV disease were analyzed
nd summarized in Table 3. Comparison between
tudies was complicated by differences in patient pop-
lations, deﬁnitions of AdV disease, assessment of
esponses, and insufﬁcient clinical information. Pa-
ients were included in the analysis only if they had
robable or deﬁnite AdV disease and received 2
oses of cidofovir [7,9,11-14,20-22]. A positive re-
ponse was deﬁned as survival or lack of active AdV
isease at the time of death. In total, 70 published
ases of deﬁnite or probable AdV disease treated with
idofovir were analyzed. Most cases were in pediatric
CT recipients, consistent with the epidemiology of
dV infections. Most patients were severely immuno-
ompromised because they received matched unre-
ated or mismatched related grafts and developed
VHD. At least 15 patients received T cell-depleted
rafts. Only 13 of 70 (19%) patients were considered
o have died from AdV disease, a rate comparable to
he 20% mortality described in the present study.
Based on this report and a review of the literature,
he use of cidofovir is associated with decreased mor-
ality from AdV disease in allogeneic SCT recipients.
otably, in case 3 and the study by Kampmann et al
22], in which patients were initially treated with riba-
irin, a delay in initiating cidofovir therapy was asso-
iated with fatal outcomes. Therefore, early detection
able 3. Literature Review of Cidofovir Use in SCT Recipients with A
No. of
Cases P/A SCT Type* D
ibaud et al [20] 1 P MUD§
egrand et al [11] 7 P MUD
ordigoni et al [9] 3 P/A MUD (2), MMRD (1)
offman et al [12] 7 P AD (6), MRD (1)
uparno et al [7]‡ 1 A MUD
jungman et al [13] 27 P/A MRD (4), MUD (18),
MMRD (5)
eruez-Ville et al [14] 3 P/A NA
uller et al [21] 10 P MRD (1), MUD (8),
MMRD (1)
ampmann et al [22] 11 P MUD (5), MMUD (3)
MMRD (1), Haplo (2)
/A indicates pediatric/adult; SCT, stem cell transplant; GVHD,
MMRD, mismatched related donor; NA, not available; AD, alter
CSF, cerebrospinal ﬂuid; MMUD, mismatched unrelated dono
Number of cases.
Culture and polymerase chain reaction.
Cidofovir dose not available.
Cord blood.f viremia and AdV disease may lead to earlier inter- Dention and improved outcomes. Cidofovir can rap-
dly inhibit AdV replication in vivo, as reﬂected by
rompt reductions in VLs in this study and the study
y Leruez-Ville et al [14]. Moreover, new lipid for-
ulations of cidofovir have increased activity against
dV in vitro and appear promising [23].
The fact that, in some cases, immune reconstitu-
ion of the SCT recipient results in resolution of AdV
isease without speciﬁc antiviral treatment suggests
hat an AdV-speciﬁc immune response is crucial for
ecovery [24,25]. In SCT recipients in whom immune
econstitution is delayed, such as the cases described
n this study, cidofovir treatment rapidly inhibits AdV
eplication, as reﬂected by dramatic decreases in AdV
Ls. Therefore, cidofovir therapy may help control
nfection until immune recovery occurs. Notably,
one of the 4 patients who survived AdV disease
elapsed within 6 months of follow-up, suggesting that
hey subsequently mounted a virus-speciﬁc immune
esponse.
Ideally, cidofovir should be evaluated as a treat-
ent for AdV disease in a placebo-controlled study. In
he meantime, given the potential for fatal outcomes,
e recommend the use of cidofovir for treatment of
dV disease in recipients of T cell-depleted or
D34 selected grafts who have severe lymphopenia
nd in patients receiving high-dose immunosuppres-
ive therapy for active GVHD. For patients who do
ot reconstitute immune responses and/or cannot tol-
rate cidofovir, immunotherapy interventions such as
us Disease
l
n* GVHD*
Definite/
Probable
AdV* AdV Site* Response*
0 1/0 Sigmoid Bx 1
5 7/0 Sigmoid Bx (7), gastric
Bx (3)
6
Blood† (2), urine† (3)
0 0/3 NA 2
4 0/7 Urine (6), blood (2),
BAL (1)
7
1 0/1 Stool 1
27 14/13 Bx (9), blood (19),
BAL (5)
23
NA 1/2 Blood PCR (3), GI (3) 2
Respiratory (3), CSF (1)
NA 0/10 GI (4), multiple (4) 9
11 0/11 Blood (11) 6
ersus-host disease; Bx, biopsy; MUD, matched unrelated donor;
onor; MRD, matched related donor; BAL, bronchoalveolar lavage;
astrointestinal tract; Haplo, haploidentical.denovir
T Cel
epletio
No
No
NA
No
1
3
NA
NA
11
graft-v
native d
r; GI, gLI should also be considered. In other allogeneic
S
c
s
a
s

o
p
i
t
p
A
T
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R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
Cidofovir Treatment of Adenovirus Disease in SCT 81CT recipients, AdV disease should be monitored
losely with AdV VLs, and immunosuppression
hould be tapered if feasible. Based on our experience
nd other published data [3,14], cidofovir therapy
hould be considered when AdV VLs increase to
100 000 copies/mL. The role of IVIG in treatment
f AdV disease also requires further study.
In addition to early diagnosis and monitoring em-
loying AdV VLs, interventions such as tapering of
mmunosuppression, treatment with cidofovir, and
he use of IVIG and DLI have the potential to im-
rove the outcome of AdV disease in SCT patients.
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